| 1 |
Guideline Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. 2003
Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ, Anonymous00228, Anonymous00229. · Indiana University, Indianapolis, USA. · Clin Infect Dis. · Pubmed #12942391 No free full text.
This publication has no abstract.
|
| 2 |
Guideline Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. 2000
Dubé MP, Sprecher D, Henry WK, Aberg JA, Torriani FJ, Hodis HN, Schouten J, Levin J, Myers G, Zackin R, Nevin T, Currier JS, Anonymous00022. · Indiana University, Indianapolis, IN 46202, USA. · Clin Infect Dis. · Pubmed #11073755 No free full text.
Abstract: Dyslipidemia is a prevalent condition that affects patients infected with human immunodeficiency virus (HIV) who are receiving antiretroviral therapy. These preliminary recommendations summarize the current understanding in this area and propose guidelines for management. Existing guidelines for the management of dyslipidemia in the general population formed the general basis for our recommendations. Data on the prevalence and treatment of dyslipidemia of HIV-infected patients, implications of treatment-related dyslipidemia in other chronically ill populations, and pharmacokinetic profiles for the available hypolipidemic agents in non-HIV populations were considered. Although the implications of dyslipidemia in this population are not fully known, the frequency, type, and magnitude of lipid alterations in HIV-infected people are expected to result in increased cardiovascular morbidity. We propose that these patients undergo evaluation and treatment on the basis of existing guidelines for dyslipidemia, with the caveat that avoidance of interactions with antiretroviral agents is paramount.
|
| 3 |
Review Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. 2005
Umeh OC, Currier JS. · Center for AIDS Research and Education, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA. · Curr HIV/AIDS Rep. · Pubmed #16091260 No free full text.
Abstract: The availability of potent combination antiretroviral therapy has changed the long-term prognosis for people living with HIV/AIDS. There is increasing concern, however, about the effect of HIV therapy on lipid disorders and subsequent development of coronary artery disease. Virtually all classes of antiretroviral drugs have been associated with some aspect of atherogenic changes in the lipid profiles. This article reviews the current literature on HIV-associated dyslipidemias and the metabolic syndrome, their potential effect on future coronary heart disease, and reviews strategies for management.
|
| 4 |
Review Cardiovascular risk associated with HIV therapy. 2002
Currier JS. · Center for AIDS Research and Education, University of California, Los Angeles, CA 90095, USA. · J Acquir Immune Defic Syndr. · Pubmed #12218440 No free full text.
This publication has no abstract.
|
|
|